Publications by authors named "Shawn A Messer"

Claim this Profile
C
Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).
Michael A Pfaller, Cecilia G Carvalhaes, Paul Rhomberg, Shawn A Messer, Mariana Castanheira

J Antibiot (Tokyo)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
Michael A Pfaller, Cecilia G Carvalhaes, Shawn A Messer, Paul R Rhomberg, Mariana Castanheira

Diagn Microbiol Infect Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).
Michael A Pfaller, Cecilia G Carvalhaes, Paul Rhomberg, Shawn A Messer, Mariana Castanheira

J Antibiot (Tokyo)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal drugs work together to treat germs causing fungal infections.
Michael A Pfaller, Shawn A Messer, Lalitagauri M Deshpande, Paul R Rhomberg, Eric A Utt

Future Microbiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program.
Michael A Pfaller, Shawn A Messer, Lalitagauri M Deshpande, Paul R Rhomberg, Eric A Utt

Antimicrob Agents Chemother· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
Shawn A Messer, Cecilia G Carvalhaes, Mariana Castanheira, Michael A Pfaller

Diagn Microbiol Infect Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Michael A Pfaller, Cecilia Carvalhaes, Shawn A Messer, Paul R Rhomberg, Mariana Castanheira

Antimicrob Agents Chemother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
Mariana Castanheira, Lalitagauri M Deshpande, Shawn A Messer, Paul R Rhomberg, Michael A Pfaller

Int J Antimicrob Agents· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Mariana Castanheira

Int J Antimicrob Agents· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Katyna Borroto-Esoda, Mariana Castanheira

Antimicrob Agents Chemother· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Mariana Castanheira

Antimicrob Agents Chemother· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Ronald N Jones, Mariana Castanheira

J Antimicrob Chemother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
Mariana Castanheira, Shawn A Messer, Paul R Rhomberg, Michael A Pfaller

Diagn Microbiol Infect Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
Michael A Pfaller, Shawn A Messer, Ronald N Jones, Mariana Castanheira

J Antibiot (Tokyo)· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Michael A Pfaller, Mariana Castanheira, Shawn A Messer, Ronald N Jones

Mycoses· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Mariana Castanheira, Shawn A Messer, Ronald N Jones, David J Farrell, Michael A Pfaller

Int J Antimicrob Agents· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.
Mariana Castanheira, Leah N Woosley, Shawn A Messer, Daniel J Diekema, Ronald N Jones

Antimicrob Agents Chemother· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
Mariana Castanheira, Shawn A Messer, Paul R Rhomberg, Rachel R Dietrich, Ronald N Jones

Mycopathologia· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
Michael A Pfaller, Mariana Castanheira, Shawn A Messer, Paul R Rhomberg, Ronald N Jones

Diagn Microbiol Infect Dis· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.
Michael A Pfaller, Shawn A Messer, Daniel J Diekema, Ronald N Jones, Mariana Castanheira

J Clin Microbiol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Michael A Pfaller, Shawn A Messer, Leah N Woosley, Ronald N Jones, Mariana Castanheira

J Clin Microbiol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Ronald N Jones, Mariana Castanheira

J Clin Microbiol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Barbara D Alexander, Melissa D Johnson, Christopher D Pfeiffer, Cristina Jiménez-Ortigosa, Jelena Catania, Shawn A Messer

Clin Infect Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).
Michael A Pfaller, Shawn A Messer, Mary R Motyl, Ronald N Jones, Mariana Castanheira

J Antimicrob Chemother· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.
Michael A Pfaller, Shawn A Messer, Mary R Motyl, Ronald N Jones, Mariana Castanheira

Antimicrob Agents Chemother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis